MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The collaboration will combine MD Anderson's clinical trials infrastructure and expertise with Astex's clinical pipeline products.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news